We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+15.92%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$384M
AUM Growth
+$106M
Cap. Flow
+$85.6M
Cap. Flow %
22.32%
Top 10 Hldgs %
38.06%
Holding
80
New
28
Increased
20
Reduced
13
Closed
19

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$13.1M
2
CVS icon
CVS Health
CVS
+$12.2M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$10.6M
4
IVC
Invacare Corporation
IVC
+$10.3M
5
KIDS icon
OrthoPediatrics
KIDS
+$9.75M

Top Sells

Rank Stock Value
1
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$39.1M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$13.1M
3
SIBN icon
SI-BONE Inc
SIBN
+$7.62M
4
SNN icon
Smith & Nephew
SNN
+$7.55M
5
CI icon
Cigna
CI
+$5.22M

Sector Composition

Rank Sector Weight
1 Healthcare 85.83%
2 Industrials 0.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESPR
51
DELISTED
Esperion Therapeutics
ESPR
$1.56M 0.41%
55,540
-151,753
-73% -$4.48M
XFOR icon
52
X4 Pharmaceuticals
XFOR
$425M
$1.31M 0.34%
+5,067
New +$1.33M
BLU
53
DELISTED
BELLUS Health Inc.
BLU
$1.21M 0.31%
+313,835
New +$1.19M
FATE icon
54
Fate Therapeutics
FATE
$308M
$1.11M 0.29%
13,432
-53,153
-80% -$5.09M
FBRX icon
55
Forte Biosciences
FBRX
$1.57B
$946K 0.25%
+1,104
New +$904K
NVRO
56
DELISTED
NEVRO CORP.
NVRO
$899K 0.23%
+6,442
New +$1.05M
STRM
57
DELISTED
Streamline Health Solutions
STRM
$796K 0.21%
+25,894
New +$742K
BOLT icon
58
Bolt Biotherapeutics
BOLT
$7.63M
$585K 0.15%
+889
New +$579K
TARS icon
59
Tarsus Pharmaceuticals
TARS
$2.81B
$456K 0.12%
+14,143
New +$523K
LBPH
60
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$267K 0.07%
+16,327
New +$267K
AKTX
61
Akari Therapeutics
AKTX
$13M
– –
-258
Closed -$382K
CI icon
62
Cigna
CI
$74.3B
– –
-25,085
Closed -$5.22M
HUM icon
63
Humana
HUM
$46.2B
– –
-7,504
Closed -$3.08M
KNSA icon
64
Kiniksa Pharmaceuticals
KNSA
$5.92B
– –
-133,648
Closed -$2.36M
MBIO icon
65
Mustang Bio
MBIO
$4.59M
– –
-1,189
Closed -$3.38M
MRK icon
66
Merck
MRK
$317B
– –
-15,635
Closed -$1.22M
PNTG icon
67
Pennant Group
PNTG
$1.36B
– –
-18,227
Closed -$1.06M
PRTA icon
68
Prothena Corp
PRTA
$458M
– –
-151,820
Closed -$1.82M
SIBN icon
69
SI-BONE Inc
SIBN
$824M
– –
-254,907
Closed -$7.62M
SLDB icon
70
Solid Biosciences
SLDB
$840M
– –
-3,045
Closed -$346K
SNN icon
71
Smith & Nephew
SNN
$12.6B
– –
-179,138
Closed -$7.55M
SRPT icon
72
Sarepta Therapeutics
SRPT
$1.79B
– –
-28,378
Closed -$4.84M
STRO icon
73
Sutro Biopharma
STRO
$421M
– –
-17,205
Closed -$3.73M
EUCRU
74
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
– –
-195,000
Closed -$2.08M
FSTX
75
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
– –
-20,445
Closed -$202K
1 2
3
4

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Endurant Capital Management held 80 positions worth $384M, up 38% from $277M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Endurant Capital Management deployed $85.6M of net new capital in Q1 2021, opening 28 new positions and adding to 20 existing holdings. Its largest new stake was Sanofi: 272,218 shares worth $13.5M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 94% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Aclaris Therapeutics, an estimated $13.1M trimmed.

  • Endurant Capital Management's largest Q1 2021 buy was Sanofi: 272,218 shares worth $13.5M.
  • Endurant Capital Management added most to Iovance Biotherapeutics in Q1 2021, an estimated $10.6M increase.
  • Endurant Capital Management's biggest Q1 2021 reduction was Aclaris Therapeutics, cutting an estimated $13.1M.
  • Endurant Capital Management fully exited Oxford Immunotec Global PLC Ordinary Shares in Q1 2021, selling an estimated $39.1M.
  • Endurant Capital Management's ten largest holdings make up 38% of its $384M portfolio in Q1 2021.
  • Endurant Capital Management opened 28 new positions and closed 19 in Q1 2021.
  • Endurant Capital Management's portfolio value rose 38% quarter-over-quarter to $384M.

Based on Endurant Capital Management's 13F filing for Q1 2021, filed 17 May 2021.